Derma Techno

Derma-Techno is a Japanese biotechnology company specializing in the development of innovative transdermal drug delivery systems (TDDS). The company utilizes its proprietary "Solid-in-Oil" (S/O) technology, which allows for the transdermal administration of large molecular weight and hydrophilic substances, such as proteins, peptides, and vaccines, by coating them with surfactants and dispersing them in an oil phase. This platform aims to replace traditional injections with non-invasive patches or topical formulations, significantly improving patient compliance and quality of life. Derma-Techno's pipeline includes transdermal versions of insulin and GLP-1 for diabetes management, as well as various vaccine candidates. The company operates as an R&D-focused entity, collaborating with academic institutions and pharmaceutical partners to commercialize its delivery solutions.